Registration of securities issued in business combination transactions

Statements of Cash Flows (Supera Pharmaceuticals, Inc.)

v3.20.4
Statements of Cash Flows (Supera Pharmaceuticals, Inc.) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from Operating activities    
Net loss $ (17,580,609) $ (3,888,249)
Increase (decrease) in cash from changes in:    
Net cash used in operating activities (11,924,941) (3,074,283)
Cash flows from Financing activities    
Net cash provided by financing activities 38,667,827 6,965,693
Net change in cash 17,985,417 (49,217)
Cash and cash equivalents and restricted cash at beginning of year 632,538 681,755
Cash and cash equivalents and restricted cash at end of year 18,617,955 632,538
Supera Pharmaceuticals, Inc. [Member]    
Cash flows from Operating activities    
Net loss (558,516) (475,937)
Increase (decrease) in cash from changes in:    
Due to/from affiliate (39,449) 12,365
Accounts payable 411,287 36,453
Interest payable 26,922 2,599
Net cash used in operating activities (159,756) (424,520)
Cash flows from Financing activities    
Proceeds from related party line of credit 160,645 422,009
Payments on related party line of credit (5,414)
Proceeds from Paycheck Protection Program loan 16,600
Net cash provided by financing activities 171,831 422,009
Net change in cash 12,075 (2,511)
Cash and cash equivalents and restricted cash at beginning of year 2,476 4,987
Cash and cash equivalents and restricted cash at end of year $ 14,551 $ 2,476